ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

daridorexant

Also written as “Daridorexant”, “ACT-541468” and “Daridorexant 25 mg”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Sleep Apnea, Obstructive · Renal Insufficiency · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageDaridorexant: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 25, 202234 company-led studies, 1 open or runningNext primary completion: Nov 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Idorsia Pharmaceuticalsits history only311 open or runningphase 4since Oct 25, 2022Aug 14, 2015Nov 22, 2027phase 3 · NCT07843329
Simcere Pharmaceutical Groupits history only20 open or runningphase 3since Aug 20, 2023Aug 20, 2023none ahead
Nxera Pharma Korea10 open or runningphase 3since Jun 11, 2025Jun 11, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Nxera Pharma Korea only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 11, 2025First study: phase 3 study in Sleep Initiation and Maintenance DisordersFirst studyNCT07028697 · 164 enrolled · South Korea

TargetBeta

“Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist”ChEMBL 37, by rule

Studies

The one study Nxera Pharma Korea leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07028697Sleep Initiation and Maintenance Disorders · South Korea3CompletedSep 23, 2025164

How it is read

Names in the registry

  • “Daridorexant”, 12 entries
  • “ACT-541468”, 12 entries
  • “Daridorexant 25 mg”, 5 entries
  • “Daridorexant 50 mg”, 4 entries
  • “Daridorexant 10 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.